ATE322897T1 - Pyruvatesterzusammenstellung und verwendungsmethode zur wiederbelebung nach ischemie- und reperfusionsvorfällen - Google Patents

Pyruvatesterzusammenstellung und verwendungsmethode zur wiederbelebung nach ischemie- und reperfusionsvorfällen

Info

Publication number
ATE322897T1
ATE322897T1 AT00970657T AT00970657T ATE322897T1 AT E322897 T1 ATE322897 T1 AT E322897T1 AT 00970657 T AT00970657 T AT 00970657T AT 00970657 T AT00970657 T AT 00970657T AT E322897 T1 ATE322897 T1 AT E322897T1
Authority
AT
Austria
Prior art keywords
composition
ester
acid esters
organ
physiological
Prior art date
Application number
AT00970657T
Other languages
English (en)
Inventor
Alfred M Ajami
Carrie A Sims
Mitchell P Fink
Original Assignee
Xanthus Life Sciences Inc
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xanthus Life Sciences Inc, Beth Israel Hospital filed Critical Xanthus Life Sciences Inc
Application granted granted Critical
Publication of ATE322897T1 publication Critical patent/ATE322897T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
AT00970657T 1999-10-07 2000-10-06 Pyruvatesterzusammenstellung und verwendungsmethode zur wiederbelebung nach ischemie- und reperfusionsvorfällen ATE322897T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15809199P 1999-10-07 1999-10-07

Publications (1)

Publication Number Publication Date
ATE322897T1 true ATE322897T1 (de) 2006-04-15

Family

ID=22566643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00970657T ATE322897T1 (de) 1999-10-07 2000-10-06 Pyruvatesterzusammenstellung und verwendungsmethode zur wiederbelebung nach ischemie- und reperfusionsvorfällen

Country Status (8)

Country Link
EP (1) EP1233767B1 (de)
JP (1) JP2003510357A (de)
CN (1) CN1377266A (de)
AT (1) ATE322897T1 (de)
AU (1) AU773407B2 (de)
CA (1) CA2386461A1 (de)
DE (1) DE60027319T2 (de)
WO (1) WO2001024793A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440480A1 (en) * 2001-03-15 2002-09-26 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
EP1496883A1 (de) * 2002-04-17 2005-01-19 Critical Therapeutics, Inc. Verfahren zur behandlung von ileus mit einer alpha-ketoalkansäure oder -ester oder -amid
CA2528144A1 (en) * 2003-06-09 2005-01-20 Mitchell P. Fink Method for treating acute pancreatitis
DE602004014140D1 (de) * 2003-06-13 2008-07-10 Univ Pittsburgh Verfahren zur behandlung von alkoholischer hepatitis
US20070276037A1 (en) * 2003-10-27 2007-11-29 Woo Yi-Ping J Cytoprotective Effects of Ethyl Pyruvate
WO2005094236A2 (en) * 2003-11-07 2005-10-13 Henry M. Jackson Foundation Activation of hypoxia-inducible gene expression
WO2006108681A2 (en) 2005-04-15 2006-10-19 Biomac Privatinstitut Für Medizinische Und Zahnmedizinische Forschung, Entwicklung Und Diagnostik Gmbh Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
JP2009533433A (ja) * 2006-04-12 2009-09-17 アレクサンダー，ランヤ，エル． ピルビン酸アルキルエステルを含む組成物とその使用
GB201511207D0 (en) 2015-06-25 2015-08-12 Xvivo Perfusion Ab Isolated organ evaluation and treatment
WO2017060422A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondrial disorders
WO2017060418A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075210A (en) * 1989-12-21 1991-12-24 The Regents Of The University Of California Preservation of the heart for transplantation
WO1995011018A1 (en) * 1991-11-27 1995-04-27 University Of Pittsburgh Medical Center Method for treating a medical patient for cardiac trauma
US5876916A (en) * 1996-03-18 1999-03-02 Case Western Reserve University Pyruvate compounds and methods for use thereof
US6086789A (en) * 1996-03-18 2000-07-11 Case Western Reserve University Medical uses of pyruvates

Also Published As

Publication number Publication date
JP2003510357A (ja) 2003-03-18
EP1233767A1 (de) 2002-08-28
AU8000500A (en) 2001-05-10
EP1233767A4 (de) 2005-02-09
DE60027319D1 (de) 2006-05-24
AU773407B2 (en) 2004-05-27
CN1377266A (zh) 2002-10-30
DE60027319T2 (de) 2007-04-05
CA2386461A1 (en) 2001-04-12
EP1233767B1 (de) 2006-04-12
WO2001024793A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
DE60027319D1 (de) Pyruvatesterzusammenstellung und verwendungsmethode zur wiederbelebung nach ischemie- und reperfusionsvorfällen
CY2364B1 (en) Cryopreservation of cultured tissue equivalents.
DE60130023D1 (de) Behandlung der nebenwirkungen von statinen
SG146691A1 (en) Methods of preparing and using stem cell compositions and kits comprising the same
ATE271886T1 (de) Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
JP2015515960A (ja) 局所非水性医薬製剤
CA2144514A1 (en) Morphogen-induced liver regeneration
UA73115C2 (en) Use of dipeptidyl peptidase iv inhibitors for treating short stature due to growth hormone deficiency
FI963867A0 (fi) Rasvahappoestereiden käyttö bioadhesiivisina aineina
DE60035574D1 (de) Formulierungen zur behandlung von krankheiten und verfahren unter deren verwendung
WO2003077835A3 (en) Sodium dodecyl sulfate compositions for inactivating prions
NO20006462L (no) Anvendelse av fumarsyrederivater i transplantasjonsmedisin
US5719174A (en) Indenoindole compounds for use in organ preservation
BR9907099A (pt) Composições farmacêuticas
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
AU709318B2 (en) Compositions that contain dialkyl (C1-C6)-ketone peroxide for preservation of organic tissues, and use of said compositions in the preservation and anatomical preparation of animal or human organic tissue
DE60332318D1 (de) Verfahren zur Preservierung von Zellen, Gewebe und Organen
US20160051581A1 (en) Delivery of argon to a recipient of biological material
HUP9603489A2 (hu) Gyógyszerkészítmény és eljárás előállítására
KR890016047A (ko) 신규 화합물
CO5160245A1 (es) Compuestos organicos inhibidores de las proteinasas de cisteina, en particular inhibidores de catepsina k de arilaminoalquilamida, y su uso farmaceutico para el tratamiento o la profilaxis de enfermedades o condiciones medicas en donde este implicada
BRPI0516814A (pt) usos do ácido 2(r,s)-d-ribo-(1',2',3',4'-tetrahidroxibutil)tiazolidina-4( r)-carboxilìco(ribcys) e métodos terapêuticos
PL350450A1 (en) Vitamin d analogues and their pharmaceutical use
WO2000057868A3 (en) Use of carbamamic acid derivatives for the treatment of viral infections

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties